{"id":"https://openalex.org/W2076374657","doi":"https://doi.org/10.1111/j.1365-2125.1990.tb03692.x","title":"The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.","display_name":"The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.","alternate_titles":[],"publication_year":1990,"publication_date":"1990-06-01","ids":{"openalex":"https://openalex.org/W2076374657","doi":"https://doi.org/10.1111/j.1365-2125.1990.tb03692.x","mag":"2076374657","pmid":"https://pubmed.ncbi.nlm.nih.gov/2378790","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1380173"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.1990.tb03692.x","doi":"https://doi.org/10.1111/j.1365-2125.1990.tb03692.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1990.tb03692.x","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2076374657"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC1380173/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086876422","display_name":"Tomas Salmonson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1296697866","display_name":"National Board of Health and Welfare","ror":"https://ror.org/01v4pc162","country_code":"SE","type":"government","lineage":["https://openalex.org/I1296697866"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T Salmonson","raw_affiliation_strings":["National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden","institution_ids":["https://openalex.org/I1296697866"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076178205","display_name":"BG Danielson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1296697866","display_name":"National Board of Health and Welfare","ror":"https://ror.org/01v4pc162","country_code":"SE","type":"government","lineage":["https://openalex.org/I1296697866"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"BG Danielson","raw_affiliation_strings":["National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden","institution_ids":["https://openalex.org/I1296697866"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109956261","display_name":"Bj\u00f6rn W\u00edkstr\u00f6m","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1296697866","display_name":"National Board of Health and Welfare","ror":"https://ror.org/01v4pc162","country_code":"SE","type":"government","lineage":["https://openalex.org/I1296697866"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B Wikstrom","raw_affiliation_strings":["National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden","institution_ids":["https://openalex.org/I1296697866"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1296697866"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":1.533,"has_fulltext":false,"cited_by_count":101,"citation_normalized_percentile":{"value":0.81526514,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"29","issue":"6","first_page":"709","last_page":"713"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recombinant-human-erythropoietin","display_name":"recombinant human erythropoietin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9959999918937683},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.9300000071525574},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":1.0},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.953000009059906},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.9480000138282776},{"id":"https://openalex.org/keywords/clearance","display_name":"clearance","score":0.9419999718666077},{"id":"https://openalex.org/keywords/half-life","display_name":"half-life","score":0.8410000205039978},{"id":"https://openalex.org/keywords/mean-residence-time","display_name":"mean residence time","score":0.9549999833106995},{"id":"https://openalex.org/keywords/concentration-time-curves","display_name":"concentration-time curves","score":0.6330000162124634},{"id":"https://openalex.org/keywords/mode-of-administration","display_name":"mode of administration","score":0.6309999823570251}],"concepts":[{"id":"https://openalex.org/C2778534260","wikidata":"https://www.wikidata.org/wiki/Q218706","display_name":"Erythropoietin","level":2,"score":0.9296532869338989},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8962588310241699},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7531967163085938},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.7175278663635254},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6797764301300049},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5137516260147095},{"id":"https://openalex.org/C3941253","wikidata":"https://www.wikidata.org/wiki/Q47270","display_name":"Half-life","level":3,"score":0.4998910427093506},{"id":"https://openalex.org/C2776390293","wikidata":"https://www.wikidata.org/wiki/Q2035485","display_name":"Subcutaneous injection","level":2,"score":0.47005951404571533},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.4196985960006714},{"id":"https://openalex.org/C110121322","wikidata":"https://www.wikidata.org/wiki/Q865811","display_name":"Distribution (mathematics)","level":2,"score":0.4106501340866089},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32780930399894714},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.16255691647529602},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004921","descriptor_name":"Erythropoietin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004921","descriptor_name":"Erythropoietin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011863","descriptor_name":"Radioimmunoassay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1365-2125.1990.tb03692.x","doi":"https://doi.org/10.1111/j.1365-2125.1990.tb03692.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.1990.tb03692.x","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1380173","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC1380173/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:2378790","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2378790","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Comparative Study"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:1380173","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC1380173/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W151260274","https://openalex.org/W1548832789","https://openalex.org/W1980178291","https://openalex.org/W1989426778","https://openalex.org/W2029738096","https://openalex.org/W2067581356","https://openalex.org/W2069678269","https://openalex.org/W2146571596","https://openalex.org/W2166051593","https://openalex.org/W2302952525","https://openalex.org/W2315613377"],"related_works":["https://openalex.org/W2466275969","https://openalex.org/W2411955250","https://openalex.org/W2438904256","https://openalex.org/W2144024266","https://openalex.org/W1534550394","https://openalex.org/W2085423203","https://openalex.org/W2044749789","https://openalex.org/W2166051593","https://openalex.org/W2043588000","https://openalex.org/W1748784274"],"abstract_inverted_index":{"1.":[0],"The":[1,24,82,115],"pharmacokinetics":[2],"of":[3,14,32,60,88,120,124,132,134,141],"recombinant":[4],"erythropoietin,":[5],"r-Epo,":[6,135],"were":[7,43,90],"evaluated":[8],"after":[9,39,68,100,111],"intravenous":[10],"and":[11,37,49,72,86,94,102,106],"subcutaneous":[12],"administration":[13,133],"50":[15],"u":[16],"kg-1":[17,48],"to":[18],"six":[19],"healthy":[20],"male":[21],"volunteers.":[22],"2.":[23],"calculated":[25],"mean":[26,83],"values":[27],"(+/-":[28,45,51,65,80,92,96,104,108],"s.d.)":[29],"for":[30,138],"volume":[31],"distribution":[33],"at":[34,63],"steady":[35],"state":[36],"clearance":[38],"an":[40],"i.v.":[41,101],"dose":[42,71],"76":[44],"33)":[46],"ml":[47,53],"12":[50],"3)":[52],"h-1":[54],"kg-1,":[55],"respectively.":[56],"3.":[57],"Serum":[58],"concentrations":[59],"r-Epo":[61],"peaked":[62],"13":[64],"6)":[66],"h":[67,77,98,110],"the":[69,73,118,122,125,130,139],"s.c.":[70,112],"bioavailability":[74],"over":[75],"72":[76],"was":[78],"36":[79],"23)%.":[81],"residence":[84],"time":[85],"half-life":[87],"erythropoietin":[89],"6.2":[91],"1.0)":[93],"4.5":[95],"0.9)":[97],"respectively":[99],"46":[103],"18)":[105],"25":[107],"12)":[109],"administration.":[113],"4.":[114],"results":[116],"demonstrate":[117],"possibility":[119],"changing":[121,129],"profile":[123],"concentration-time":[126],"curve":[127],"by":[128],"mode":[131],"with":[136],"implications":[137],"time-course":[140],"clinical":[142],"response.":[143]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2076374657","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
